Investment Rating - The report maintains an "Overweight" rating for the pharmaceutical and biotechnology sector [9]. Core Insights - The pharmaceutical index increased by 3.64% during the week of June 30 to July 4, outperforming both the ChiNext and CSI 300 indices, indicating a positive market sentiment towards innovative drugs and brain-computer interface technologies [14][15]. - The report emphasizes the strong performance of PD-1 Plus drugs, which are seen as a driving force in the current market recovery, supported by significant business development (BD) deals and a favorable industry trend [2][15]. - The outlook for 2025 remains optimistic, focusing on innovative drugs, new technologies, and the restructuring of supply chains [3][16]. Summary by Sections 1. Industry Overview - The pharmaceutical sector is experiencing a rebound, with innovative drugs and brain-computer interfaces leading the charge. The report highlights the importance of PD-1 Plus drugs in this recovery [14][15]. 2. Innovative Drug Selection - PD-1 Plus drugs are gaining traction, with significant overseas collaborations and clinical trial advancements. The report notes that companies like Innovent Biologics and BeiGene are at the forefront of this trend [20][21]. - The report suggests focusing on companies with promising PD-1/IL-2 combinations and those that have successfully entered international markets [23]. 3. Investment Strategies - The report outlines a strategy focusing on core stocks in the innovative drug space, particularly those with strong growth potential and upcoming clinical data releases [3][17]. - Key companies to watch include Innovent Biologics, Zai Lab, and others involved in PD-1 Plus and related technologies [4][17]. 4. Market Performance - The report provides a comparative analysis of the performance of various indices, noting that the innovative drug index has outperformed the broader pharmaceutical index and the CSI 300 index since the beginning of 2025 [41][42]. - The report also highlights the performance of specific stocks within the innovative drug sector, indicating a positive trend for companies like Zai Lab and BeiGene [45]. 5. Future Outlook - The report anticipates continued optimism in the pharmaceutical sector, particularly around innovative drugs and new technologies such as AI in healthcare and rehabilitation robotics [3][16]. - The focus will be on identifying high-growth opportunities in the innovative drug space and leveraging the ongoing restructuring of supply chains [3][19].

Core Insights - The data indicates significant trading volume increases for various companies, suggesting heightened investor interest and potential market movements [1][2][3][4][5] Group 1: Companies with Notable Volume Increases - 阳光能源 (00757) reported a volume ratio of 2.35, indicating strong trading activity [2] - 长城汽车 (02333) had a volume ratio of 2.21, reflecting increased investor engagement [2] - 郑煤机 (00564) showed a volume ratio of 1.92, suggesting a notable rise in trading [2] Group 2: Additional Companies with Increased Trading Activity - 万国数据-SW (09698) recorded a volume ratio of 1.83, indicating significant market interest [2] - 映恩生物-B (09606) had a volume ratio of 1.78, reflecting heightened trading activity [2] - 超盈国际控股 (02111) reported a volume ratio of 1.71, suggesting increased investor focus [2] Group 3: Companies with Moderate Volume Ratios - 中国能源建设 (03996) had a volume ratio of 1.70, indicating a solid level of trading activity [2] - 亚信科技 (01675) reported a volume ratio of 1.60, reflecting moderate investor interest [2] - 金宝通 (00320) showed a volume ratio of 1.53, suggesting a rise in trading volume [2] Group 4: Companies with Lower Volume Ratios - 中国水务 (00855) had a volume ratio of 1.52, indicating stable trading activity [2] - 广汽集团 (02238) reported a volume ratio of 1.52, reflecting consistent investor engagement [2] - 凯莱英 (06821) showed a volume ratio of 1.52, suggesting steady trading interest [2]

Core Viewpoint - The rise of domestic innovative drugs in China since 2025 is significantly driven by Business Development (BD) strategies, allowing companies to monetize their research through partnerships with multinational pharmaceutical firms [1][2]. Company Overview - A notable player in this space is Anmai Biotech, which is preparing for an IPO in Hong Kong and has gained attention for its BD transactions, accumulating over $2.1 billion in deal value since the end of 2023, ranking second globally in the TCE bispecific antibody sector [1][3]. - The founder, Wu Chenbing, previously served as the Chief Scientific Officer at 3SBio, indicating a strong lineage of expertise and a shift in Chinese biotech from "following" to "leading" in innovation [1][3]. Financial Performance - As of the end of 2024, Anmai Biotech's cash and equivalents are sufficient for only 12 months of operations, highlighting the importance of clinical progress and commercialization capabilities for its transition from a "transaction star" to a "profit benchmark" [2][8]. - The company reported a revenue of 459 million yuan in 2024, with a net profit of 47.7 million yuan, following a loss of 595 million yuan in 2023 primarily due to R&D expenses [7]. Product Pipeline - Anmai Biotech's lead product, EMB-01, is a bispecific antibody targeting EGFR/cMET, which is among the first to enter Phase II trials for colorectal cancer, with a market potential driven by the increasing incidence of the disease [6][7]. - The global bispecific antibody market is projected to grow from $13.4 billion in 2024 to over $220 billion by 2034, with a compound annual growth rate of 32.4% [6]. Strategic Partnerships - The company has engaged in multiple licensing agreements, including a significant deal with Vignette Bio valued at $635 million for EMB-06, and a recent global licensing agreement with Juri for KLK2/CD3 TCE with a potential value of $210 million [7]. Leadership and Expertise - The leadership team includes Dr. Zhu Yonghong, who brings extensive international clinical development experience, complementing Wu Chenbing's background in drug development [4]. - Anmai Biotech's FIT-Ig technology platform, patented in the U.S. in 2018, is a key competitive advantage, addressing stability issues in traditional bispecific antibodies [4][5].

Market Overview - On July 2, the Hang Seng Index rose by 0.62%, closing at 24,221.41 points, with a net inflow of HKD 5.036 billion through the southbound trading channel [1] - The total trading volume for the southbound trading was HKD 128.967 billion, with a net buy of HKD 5.036 billion [1] Southbound Trading Details - The Shanghai Stock Exchange's southbound trading had a total transaction amount of HKD 81.984 billion, with a net buy of HKD 1.279 billion [1] - The Shenzhen Stock Exchange's southbound trading had a total transaction amount of HKD 46.983 billion, with a net buy of HKD 3.757 billion [1] Active Stocks - In the Shanghai Stock Exchange's southbound trading, Alibaba-W had the highest transaction amount at HKD 3.170 billion, followed by Chongqing Iron & Steel and Xiaomi Group-W with transaction amounts of HKD 2.929 billion and HKD 2.827 billion, respectively [1] - In terms of net buy amounts, the Yingfu Fund led with a net buy of HKD 1.674 billion, while Alibaba-W had the highest net sell amount at HKD 788 million, closing down by 0.36% [1] Shenzhen Stock Exchange Active Stocks - In the Shenzhen Stock Exchange's southbound trading, Alibaba-W also topped the transaction amount at HKD 2.407 billion, followed by Tencent Holdings and Xiaomi Group-W with transaction amounts of HKD 1.589 billion and HKD 1.582 billion, respectively [2] - The stock with the highest net buy was Innovent Biologics, with a net buy of HKD 651 million, closing up by 1.15%, while Alibaba-W had the highest net sell amount at HKD 945 million, also closing down by 0.36% [2]

Market Overview - On July 2, the Hang Seng Index rose by 0.62%, with southbound funds totaling HKD 128.97 billion in trading volume, including HKD 67.00 billion in buying and HKD 61.97 billion in selling, resulting in a net buying amount of HKD 5.04 billion [1] Southbound Trading Activity - The southbound trading through Stock Connect (Shenzhen) had a total trading volume of HKD 46.98 billion, with HKD 25.37 billion in buying and HKD 21.61 billion in selling, leading to a net buying amount of HKD 3.76 billion [1] - The southbound trading through Stock Connect (Shanghai) had a total trading volume of HKD 81.98 billion, with HKD 41.63 billion in buying and HKD 40.35 billion in selling, resulting in a net buying amount of HKD 1.29 billion [1] Active Stocks - Alibaba-W had the highest trading volume among southbound funds, totaling HKD 55.77 billion, followed by Xiaomi Group-W at HKD 44.08 billion and Chongqing Steel at HKD 37.21 billion [1] - The net buying stocks included 8 companies, with the largest net buying amount for Yingfu Fund at HKD 16.74 billion, followed by Innovent Biologics at HKD 6.51 billion and Meituan-W at HKD 3.38 billion [1] Continuous Net Buying and Selling - Two stocks, namely SMIC and Innovent Biologics, experienced continuous net buying for over three days, with SMIC leading at a total net buying of HKD 59.43 billion and Innovent Biologics at HKD 17.83 billion [2] - The stocks with the highest net selling included Tencent Holdings, Xiaomi Group-W, and Alibaba-W, with total net selling amounts of HKD 22.53 billion, HKD 3.74 billion, and HKD 3.08 billion respectively [2] Summary of Active Stocks on July 2 - The following table summarizes the active stocks with their trading amounts, net buying amounts, and daily price changes: - Yingfu Fund: Trading Amount HKD 1689.30 million, Net Buying HKD 1674.46 million, Daily Change 0.49% - Innovent Biologics: Trading Amount HKD 1079.97 million, Net Buying HKD 651.12 million, Daily Change 1.15% - Meituan-W: Trading Amount HKD 2976.06 million, Net Buying HKD 338.09 million, Daily Change 0.56% - SMIC: Trading Amount HKD 3274.27 million, Net Buying HKD 317.79 million, Daily Change -2.57% - Chongqing Steel: Trading Amount HKD 3720.82 million, Net Buying HKD 144.80 million, Daily Change 91.11% - Xiaomi Group-W: Trading Amount HKD 4408.50 million, Net Selling HKD 36.95 million, Daily Change 0.33% - Tencent Holdings: Trading Amount HKD 3438.30 million, Net Selling HKD 62.96 million, Daily Change -0.30% - Alibaba-W: Trading Amount HKD 5576.67 million, Net Selling HKD 173.65 million, Daily Change -0.36% [2]

Group 1 - On July 2, 2025, Alibaba-W (09988), Chongqing Steel (01053), and Xiaomi Group-W (01810) were the top three companies by trading volume in the Southbound Stock Connect, with trading amounts of 3.17 billion, 2.93 billion, and 2.83 billion respectively [1] - In the Southbound Stock Connect for the Shenzhen-Hong Kong Stock Connect, Alibaba-W (09988), Tencent Holdings (00700), and Xiaomi Group-W (01810) also ranked as the top three, with trading amounts of 2.41 billion, 1.59 billion, and 1.58 billion respectively [1] Group 2 - In the Southbound Stock Connect, the top ten active trading companies included Alibaba-W (09988) with a trading amount of 3.17 billion and a net buy of -788 million, Chongqing Steel (01053) with 2.93 billion and a net buy of 116 million, and Xiaomi Group-W (01810) with 2.83 billion and a net buy of -222 million [2] - The Southbound Stock Connect for Shenzhen-Hong Kong also featured Alibaba-W (09988) with a trading amount of 2.41 billion and a net buy of -945 million, Tencent Holdings (00700) with 1.59 billion and a net buy of -259 million, and Xiaomi Group-W (01810) with 1.58 billion and a net buy of -147 million [2]

Group 1: Market Overview - On July 2, the Hong Kong stock market saw a net inflow of 50.36 billion HKD from northbound trading, with 12.79 billion HKD from the Shanghai Stock Connect and 37.57 billion HKD from the Shenzhen Stock Connect [1] - The most bought stocks included the Tracker Fund of Hong Kong (02800), Innovent Biologics (01801), and Meituan-W (03690) [1] - The most sold stocks were Alibaba-W (09988), Tencent (00700), and Xiaomi Group-W (01810) [1] Group 2: Stock Performance - Alibaba-W had a buy amount of 11.91 billion HKD and a sell amount of 19.79 billion HKD, resulting in a net outflow of 7.88 billion HKD [2] - Xiaomi Group-W had a buy amount of 13.02 billion HKD and a sell amount of 15.25 billion HKD, leading to a net outflow of 2.22 billion HKD [2] - Tencent had a buy amount of 7.39 billion HKD and a sell amount of 11.10 billion HKD, resulting in a net outflow of 3.71 billion HKD [2] Group 3: Sector Insights - The Tracker Fund of Hong Kong (02800) received a net inflow of 16.74 billion HKD, with analysts suggesting that the current market conditions provide a favorable window for investment, particularly in the technology sector [5] - Innovent Biologics (01801) and 3SBio (01530) received net inflows of 6.51 billion HKD and 1.09 billion HKD, respectively, following new measures to support the development of innovative drugs [5] - Meituan-W (03690) saw a net inflow of 3.38 billion HKD, while Alibaba-W and Tencent experienced significant net outflows [6] Group 4: Company-Specific Developments - Chongqing Steel (01053) received a net inflow of 1.44 billion HKD amid rumors of production cuts in Tangshan, which could impact capacity utilization [6] - Pop Mart (09992) received a net inflow of 1.22 billion HKD after being recognized in Time magazine's list of the "100 Most Influential Companies" for 2025 [7] - Xiaomi's Yu7 model orders exceeded expectations, leading to an upward revision of shipment forecasts for 2025 to 2027 [8]

Core Viewpoint - The recent policy measures introduced by the National Healthcare Security Administration and the National Health Commission aim to support the high-quality development of innovative drugs in China, addressing key challenges in the industry from research to market access [1][4]. Group 1: Policy Measures - The new measures include 16 targeted initiatives designed to tackle the difficulties in research, payment, and hospital access for innovative drugs, which are seen as a significant boost for the domestic pharmaceutical innovation engine [1][2]. - The policy encourages commercial health insurance to establish investment funds for innovative drug research, addressing long-term funding shortages [2]. Group 2: Research and Development - The measures allow for the opening of national unified medical insurance data, providing pharmaceutical companies and research institutions with access to critical data resources, which will help in efficiently identifying research targets and optimizing development pipelines [1][3]. - Companies can now apply for "point-to-point" policy guidance from the insurance department as soon as their new drug application is accepted, clarifying key elements for market access [2]. Group 3: Payment and Market Access - The introduction of a "commercial health insurance innovative drug directory" provides a new pathway for high-value innovative drugs that may not fit into basic medical insurance coverage, allowing for price confidentiality and exemption from certain regulations [3]. - The measures state that medical institutions cannot restrict the allocation of innovative drugs based on "drug proportion" or the number of drugs in the directory, enhancing the chances for high-value innovative drugs to enter hospitals [3]. Group 4: Market Outlook - The innovative drug sector is expected to continue its upward trend, driven by a recognition of the commercial model and the long-term value of leading companies, with a positive outlook for the industry’s fundamentals [5][7]. - The current market environment is characterized by a revaluation of research assets, with a focus on data asset pricing rather than business development (BD) pricing, indicating that high-quality research data will attract reasonable market valuations [6]. Group 5: Company Highlights - Heng Rui Medicine (恒瑞医药) is projected to achieve a revenue of 27.985 billion yuan in 2024, reflecting a 22.6% increase, with innovative drug sales expected to rise from 38.1% of total revenue in 2022 to 46.3% in 2024 [8]. - Three Life Pharmaceuticals (三生制药) has made significant strides in international collaboration, with a recent deal with Pfizer valued at up to $6.15 billion, showcasing the clinical value of its dual antibody platform [9].

Core Viewpoint - The article highlights significant policy support for the innovative drug sector in China, which is expected to drive growth and investment opportunities in the industry [2][6][10]. Policy Support - The National Healthcare Security Administration and the National Health Commission issued measures to support the high-quality development of innovative drugs, including 16 specific initiatives across five areas [2][6]. - The measures include utilizing healthcare data for innovative drug research and encouraging commercial health insurance to expand investment in innovative drugs [6][7]. Market Reaction - Following the announcement of the supportive policies, innovative drug stocks surged, with companies like Sali Medical and Guizhou BaiLing hitting the daily limit, and others like Shuyitai and Hotgen Biotech seeing significant gains [3][5]. Future Outlook - Analysts predict that 2025 will be a pivotal year for domestic innovative drug companies to expand internationally, driven by technological innovation and market growth [4][12]. - The innovative drug market is expected to continue expanding, with a notable increase in overseas licensing deals and a shift from capital-driven growth to profit-driven growth [11][12]. Investment Opportunities - Investment strategies should focus on potential companies that may expand internationally, particularly in areas such as next-generation immunotherapy, antibody-drug conjugates (ADC), and breakthroughs in chronic disease treatments [11][12].

Core Insights - The Hong Kong Innovation Drug Index (931787) has shown a positive performance, with significant increases in constituent stocks such as Zai Lab (11.01%) and Cloudmed (9.27%) [1] - The Hong Kong Innovation Drug ETF (513120) has experienced active trading, with a turnover of 33.61% and a total transaction volume of 4.472 billion [1] - The ETF has seen a continuous net inflow of funds over the past 14 days, totaling 3.159 billion [1][2] Market Performance - As of June 27, the Hong Kong Innovation Drug ETF has achieved a net value increase of 86.07% over the past year, ranking 1st out of 120 in QDII equity funds [2] - The ETF's highest monthly return since inception was 23.82%, with the longest consecutive monthly gain being 4 months and a maximum cumulative increase of 44.08% [2] - The average monthly return during the rising months is 7.59% [2] Valuation Metrics - The latest price-to-earnings ratio (PE-TTM) for the Hong Kong Innovation Drug ETF is 32.62, which is below the 83.82% historical level over the past five years, indicating a low valuation [2] - The ETF closely tracks the Hong Kong Innovation Drug Index, which includes up to 50 listed companies primarily engaged in innovative drug research and development [2] Industry Developments - The top ten weighted stocks in the Hong Kong Innovation Drug Index account for 71.99% of the index, with notable companies including Innovent Biologics and BeiGene [3] - The approval of a new drug by the National Medical Products Administration (NMPA) for long-term weight control in adults marks a significant development in the industry [3] - Recent reports suggest that China's innovative drug sector is becoming a global supplier of innovative therapies, driven by high efficiency and low-cost development advantages [4] Investment Opportunities - The Hong Kong Innovation Drug ETF provides exposure to leading companies in the innovative drug sector, such as Innovent Biologics and CanSino Biologics [4] - The ETF supports T+0 trading, enhancing liquidity and allowing investors to conduct multiple transactions within a trading day [4]